Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Behavioral Sciences (Basel, Switzerland)|February 27, 2026
From Diagnosis to Behaviour Change: Applying the Health Action Process Approach to Smoking Cessation After Head and Neck CancerAnaëlle Préaubert, Agnès Dupret-Bories, Emilien Chabrillac, et al.
The Journal of Biological Chemistry|December 3, 2004
A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activationAlexandra Montagner, Armelle Yart, Marie Dance, et al.
Biochemical and Biophysical Research Communications|January 12, 2002
Identification of a region critical for proteolysis of the human growth hormone receptorFrançoise Conte, Jean Pierre Salles, Patrick Raynal, et al.
The Journal of Biological Chemistry|March 28, 2002
A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acidArmelle Yart, Serge Roche, Reinhard Wetzker, et al.
The Journal of Biological Chemistry|June 22, 2006
The adaptor protein Gab1 couples the stimulation of vascular endothelial growth factor receptor-2 to the activation of phosphoinositide 3-kinaseMarie Dance, Alexandra Montagner, Armelle Yart, et al.
FEBS Letters|April 28, 2006
Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1Nadine Hanna, Alexandra Montagner, Wen Hwa Lee, et al.
Molecular and Cellular Biology|November 21, 2007
Signal strength dictates phosphoinositide 3-kinase contribution to Ras/extracellular signal-regulated kinase 1 and 2 activation via differential Gab1/Shp2 recruitment: consequences for resistance to epidermal growth factor receptor inhibitionCarla Sampaio, Marie Dance, Alexandra Montagner, et al.
Molecular and Cellular Biology|March 24, 2010
Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signalingThomas Edouard, Jean-Philippe Combier, Audrey Nédélec, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 29, 2012
Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short statureAudrey De Rocca Serra-Nédélec, Thomas Edouard, Karine Tréguer, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2014
LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesityMylène Tajan, Aurélie Batut, Thomas Cadoudal, et al.
Pageof 5